Holen Sie sich die Stockscreener-App
24.51
1.16%
0.28
Handel nachbörslich:
24.54
0.03
+0.12%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$24.23
Offen:
$24.2
24-Stunden-Volumen:
39.98M
Relative Volume:
0.83
Marktkapitalisierung:
$139.35B
Einnahmen:
$63.83B
Nettoeinkommen (Verlust:
$10.77B
KGV:
13.04
EPS:
1.8799
Netto-Cashflow:
$12.44B
1W Leistung:
-1.09%
1M Leistung:
+1.91%
6M Leistung:
+10.70%
1J Leistung:
-16.26%
1-Tages-Spanne:
$24.16
$24.53
1-Wochen-Bereich:
$24.16
$24.95
52-Wochen-Spanne:
$20.91
$29.36
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Vergleichen Sie PFE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.51 | 137.76B | 63.83B | 10.77B | 12.44B | 1.8799 |
|
LLY
Lilly Eli Co
|
802.83 | 734.54B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
193.22 | 462.69B | 92.15B | 25.12B | 18.18B | 10.36 |
|
ABBV
Abbvie Inc
|
229.57 | 400.78B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
131.43 | 253.15B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
84.79 | 209.61B | 63.43B | 16.42B | 14.72B | 6.4861 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Pfizer: XTANDI Plus Leuprolide Cuts Death Risk 40% In High-Risk NmHSPC Phase 3 Study - Nasdaq
Pfizer (PFE) Reports Positive PADCEV Trial Results at ESMO 2025 - GuruFocus
Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last? - ts2.tech
XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer - Pfizer
Pfizer Co & Astellas announce final overall survival results from Phase 3 Embark study for Xtandi in combination with Leuprolide - MarketScreener
40.3% lower risk of death — XTANDI + leuprolide raises 8‑yr OS to 78.9% in nmHSPC (Pfizer) - Stock Titan
Pfizer says Braftovi + Mektovi shows sustained long-term survival in patients with advanced lung cancer - MarketScreener
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer - Business Wire
Pfizer Stock Forecast – PFE Rises to $24.51 as Metsera Buyout and Seagen Synergies Drive 2025 Growth - TradingNEWS
What insider trading reveals about Pfizer Inc. stockWeekly Investment Recap & Reliable Breakout Stock Forecasts - nchmf.gov.vn
How Positive Phase 3 Cancer Drug Results at Pfizer (PFE) Have Changed Its Investment Story - simplywall.st
PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer - Pfizer
Will Pfizer Inc. stock benefit from sector rotationMarket Activity Recap & Weekly Watchlist for Hot Stocks - nchmf.gov.vn
Astellas Pharma Inc. and Pfizer Inc. Announces Positive Results from the Pivotal Phase 3 EV-303 Clinical Trial (Also Known as Keynote-905) for PADCEV - MarketScreener
Will Pfizer Inc. (PFE) stock deliver compounding returns2025 Key Highlights & Reliable Price Action Trade Plans - nchmf.gov.vn
Pfizer and Astellas announce positive results from phase 3ev-303 clinical trial for Padcev in combination with Keytruda - MarketScreener
Why Pfizer Inc. stock is considered a top pick2025 Top Decliners & Free Growth Oriented Trading Recommendations - nchmf.gov.vn
Astellas-Pfizer's combination therapy halves risk of death in bladder cancer patients - MarketScreener
Will Pfizer Inc. stock attract ESG investorsJuly 2025 Sector Moves & Smart Money Movement Tracker - nchmf.gov.vn
Did Pfizer Overpay For Yet Another Acquisition? (NYSE:PFE) - Seeking Alpha
Pfizer: World-Leading Drug Pipeline Sets Stage For Major Long-Term Potential (NYSE:PFE) - Seeking Alpha
How Pfizer Inc. (Common Stock) (PFEB) stock behaves under inflation pressure2025 Volatility Report & Low Risk Profit Maximizing Plans - nchmf.gov.vn
Will Pfizer Inc. stock split again soonJuly 2025 PreEarnings & AI Enhanced Execution Alerts - nchmf.gov.vn
Is Pfizer Inc. stock a buy on dipsJuly 2025 Sector Moves & AI Driven Price Forecasts - nchmf.gov.vn
Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress - GlobeNewswire Inc.
Can Pfizer Inc. (PFE) stock deliver strong annual returnsQuarterly Trade Review & Consistent Income Trade Recommendations - nchmf.gov.vn
Is Pfizer Inc. stock a good choice for value investors2025 Year in Review & Technical Pattern Based Signals - nchmf.gov.vn
RSI Check: Is Pfizer Inc. stock positioned well for digital economy2025 Market Trends & Step-by-Step Trade Execution Guides - nchmf.gov.vn
Can Pfizer Inc. (PFE) stock retain market dominance2025 Key Lessons & Long-Term Growth Stock Strategies - nchmf.gov.vn
Why Pfizer Inc. stock attracts high net worth investorsPrice Action & Reliable Breakout Forecasts - nchmf.gov.vn
Risk Off: Is Pfizer Inc. stock a good choice for value investors2025 Key Highlights & Entry Point Confirmation Signals - nchmf.gov.vn
Metsera, Inc. Announces Special Meeting for Merger Vote with Pfizer - TipRanks
Popular birth control is linked to brain tumors in new study — as over 1,000 women sue Pfizer over health risks - New York Post
Why Pfizer Inc. (Common Stock) (PFEB) stock is upgraded to buyWeekly Risk Report & Safe Capital Growth Trade Ideas - nchmf.gov.vn
Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs? - Benzinga
What’s Behind The Slump In Pfizer Stock? - Forbes
RFPs: Pfizer Clostridioides difficile (C. difficile) Research Collaboration Program - fundsforNGOs
Pfizer Faces Growing Legal Storm Over Depo-Provera as Brain Tumor Lawsuits Surge - The Legal Examiner
Day 9 of Loss Streak for Pfizer Stock with -11% Return (vs. -3.8% YTD) [10/16/2025] - Trefis
Pfizer chairman/CEO to be honored by Israel’s largest university - New Jersey Jewish News
QSM Asset Management Buys $6.8 Million of Pfizer Stock as Pharma Giant Lags Market - sharewise.com
ASSET PLANNING Exits Full Stake in Pfizer Worth $2.7 Million - The Globe and Mail
Pfizer CEO touts Trump drug-price deal amid vaccine doubts - Crain's New York Business
Pfizer Goes All In On TrumpRx. Is Pfizer Stock Now A Buy? - Investor's Business Daily
Institutional Investors May Adopt Severe Steps After Pfizer Inc.'s (NYSE:PFE) Latest 5.0% Drop Adds to a Year Losses - 富途牛牛
Pfizer Strikes $70B Deal with Trump--But Warns China Is Racing Ahead in Biotech War - Yahoo Finance
Acquired Hemophilia A Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Novo Nordisk, Sanofi, Pfizer, Belief BioMed, Centessa Pharma - Barchart.com
Pfizer’s Q3 2025 Earnings: What to Expect - MSN
Pfizer’s Q3 2025 Earnings: What To Expect - Barchart.com
Pfizer: Don't Forget About Value During AI Frenzy (NYSE:PFE) - Seeking Alpha
Day 8 of Loss Streak for Pfizer Stock with -11% Return (vs. -3.1% YTD) [10/15/2025] - Trefis
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.21%
3.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):